argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
22 jan 2016 - 17:48
Statutaire naam
argenx SE
Titel
argenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors
Bericht
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
22 January 2016
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has successfully closed the transaction with funds advised by subsidiaries of Federated Investors, Inc. (USA). 1,480,420 shares have been issued at € 10.79. The new shares have been admitted to listing on Euronext Brussels.
Datum laatste update: 13 januari 2026